Yaso Therapeutics

Executive Summary

Yaso Therapeutics is a private, Phase 1 biotech company based in San Diego, developing a novel nanotechnology-based drug, PPCM (Yaso Gel), for the prevention and treatment of sexually transmitted diseases (STDs). PPCM creates a nanoscale barrier that surrounds viruses and bacteria, preventing infection. Its broad-spectrum activity against viral and bacterial pathogens, including drug-resistant strains, positions it as a potential game-changer in global STD prevention. The company was founded in 2021 and is currently in early clinical development, targeting a significant unmet need in sexual health. While funding details and valuation are undisclosed, the platform's versatility suggests potential expansion into other infectious disease indications. Yaso's approach leverages nanotechnology to deliver a new generation of protection, addressing the urgent need for effective, non-antibiotic-based prevention strategies. With growing awareness of antimicrobial resistance and the global burden of STDs, Yaso's PPCM gel could offer a compelling alternative to traditional barrier methods and treatments, pending clinical validation.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout60% success
• Q1 2027Phase 2 trial initiation50% success
• Q4 2026Strategic partnership or funding round40% success